Comparing the current results to its competitors, Kodiak Sciences Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 11.78 %, recorded in the same quarter.
Kodiak Sciences Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 41.37 %
Kodiak Sciences Inc 's Comment on Competition and Industry Peers
The competitive landscape includes the Zenkuda program in the DAYBREAK study, which aims to evaluate Zenkuda as a biologic treatment for VEGF-driven retinal vascular diseases. The DAYBREAK study's topline data for the one-year primary endpoint are expected in the third quarter of 2026. Additionally, completed Phase 3 studies GLOW1 and GLOW2 have focused on patients with diabetic retinopathy.
Beam Therapeutics Inc's business model revolves around developing precision genetic medicines using base editing technology. They aim to address genetic diseases by making precise edits to a patient's DNA at the molecular level, providing potential treatments that are highly targeted and minimally invasive.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Outlook Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing monoclonal antibody-based therapies for various ophthalmic indications. Their business model revolves around leveraging their expertise in developing cost-effective, innovative treatments that address unmet medical needs in the ophthalmic market.
Opthea Limited operates as a clinical stage biotechnology company, primarily focused on the development of novel therapies for the treatment of eye diseases. The company pursues its business model by leveraging its expertise in the discovery and development of innovative therapeutics, while collaborating with strategic partners and conducting clinical trials to bring its products to market.
Sources:
Kodiak Sciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Kodiak Sciences Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
